Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014)

Vaccine

Volumn 33, Issue 14, 2015, Pages 1633-1658

  Wu, David Bin Chia ^a   Chaiyakunapruk, Nathorn ^a,b,c,d   Chong, Huey Yi ^a   Beutels, Philippe ^e,f  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cost benefit; Cost effectiveness; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PREVENAR13;

ANTIBIOTIC RESISTANCE; CHILDHOOD; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HERD; HUMAN; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; CHILD; ECONOMICS; INFANT; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; TIME;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TIME FACTORS;

EID: 84925067641     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.081     Document Type: Review

References (144)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
2. Fedson D.S., Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, 17(Suppl. 1):S11-S18.
3. Dagan R., Klugman K. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008, 8:785-795. PMID: 19022193.
4. Linares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010, 16(5):402-410.
5. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I. Clin Infect Dis 2000, 30(1):100-121.
6. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(10):760-768.
7. Weil-Olivier C., van der Linden M., de Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 2012, 12.
8. Hanquet G., Lernout T., Vergison A., Verhaegen J., Kissling E., Tuerlinckx D., et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 2011, 29:2856-2864. PMID: 21342667.
9. Jauneikaite E., Jefferies J.M., Hibberd M.L., Clarke S.C. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 2012, 30(24):3503-3514.
10. Domingues C.M., Verani J.R., Montenegro Renoiner E.I., de Cunto Brandileone M.C., Flannery B., de Oliveira L.H., et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014, 2(6):464-471.
11. Invasive pneumococcal disease in birth cohorts vaccinated with PCV7 and/or PHiD-CV in Quebac: an update. The 31st meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013) 2013, P. De Wals, B. Lefebvre, F. Markowski, G. Deceuninck, F. Defay, N. Boulianne (Eds.).
12. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland. The 31st annual meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013) 2013, H. Rinta-Kokko, J. Jokinen, L. Siira, A.A. Palmu, M.J. Virtanen, H. Nohynek (Eds.).
13. Moore C.E., Paul J., Foster D., Mahar S.A., Griffiths D., Knox K., et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 2014, 210(7):1001-1011.
14. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine 2007, 25:1355-1367. PMID: 17208339.
15. Boonacker C.W.B., Broos P.H., Sanders E.A.M., Schilder A.G.M., Rovers M.M. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 2011, 29(3):199-211.
16. Isaacman D., Strutton D., Kalpas E., Horowicz-Mehler N., Stern L., Casciano R., et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther 2008, 30:341-357. PMID: 18343273.
17. McClure C.A., Ford M.W., Wilson J.B., Aramini J.J. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: recommendations and expected benefits. Can J Infect Dis Med Microbiol 2006, 17:19-26. PMID: 18418479.
18. Ray G.T. Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe. Expert Rev Pharmacoecon Outcomes Res 2008, 8(4):373-393.
19. van de Vooren K., Duranti S., Curto A., Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics 2014, 32(1):29-45.
20. Farkouh R.A., Klok R.M., Postma M.J., Roberts C.S., Strutton D.R. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines 2012, 11(10):1235-1247.
21. XE Live Exchange Rates 2014, Available from: http://www.xe.com/ [cited 12.02.14].
22. Cost of Living Index 2014, Available from: http://www.numbeo.com/cost-of-living/rankings.jsp [cited 12.02.14].
23. Drummond M., Stoddary O.B.B., Torrance G.G. Methods for the economic evaluation of health care programmes 1997, Oxford University Press, Oxford. 2nd ed.
24. O'Brien M., Prosser L., Paradise J., Ray G., Kulldorff M., Kurs-Lasky M., et al. New vaccines against otitis media: projected benefits and cost-effectiveness. Pediatrics 2009, 123:1452-1463. PMID: 19482754.
25. Chuck A.W., Jacobs P., Tyrrell G., Kellner J.D. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010, 28:5485-5490. PMID: 20554066.
26. Rubin J., McGarry L., Strutton D., Klugman K., Pelton S., Gilmore K., et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643. PMID: 20883739.
27. Talbird S., Taylor T., Knoll S., Frostad C., Garcia Marti S. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine 2010, 28(Suppl. 6):23-29. PMID: 21075266.
28. Kim S.-Y., Lee G., Goldie S. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis 2010, 10:260. PMID: 20815900.
29. Sartori A.M., de Soarez P.C., Novaes H.M. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Community Health 2012, 66(3):210-217.
30. Robberstad B., Frostad C.R., Akselsen P.E., Kværner K.J., Berstad A.K.H. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 2011, 29(47):8564-8574.
31. Newall A.T., Creighton P., Philp D.J., Wood J.G., MacIntyre C.R. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine 2011, 29(45):8077-8085.
32. Tyo K.R., Rosen M.M., Zeng W., Yap M., Pwee K.H., Ang L.W., et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 2011, 29(38):6686-6694.
33. Urueña A., Pippo T., Betelu M.S., Virgilio F., Giglio N., Gentile A., et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 2011, 29(31):4963-4972.
34. Díez-Domingo J., Ridao-López M., Gutiérrez-Gimeno M.V., Puig-Barberá J., Lluch-Rodrigo J.A., Pastor-Villalba E. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine 2011, 29(52):9640-9648.
35. Knerer G., Ismaila A., Pearce D. Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ 2012, 15(1):61-76.
36. Earnshaw S.R., McDade C.L., Zanotti G., Farkouh R.A., Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis 2012, 12.
37. By A., Sobocki P., Forsgren A., Silfverdal S.A. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther 2012, 34(1):177-189.
38. Castañeda-Orjuela C., Alvis-Guzmán N., Velandia-González M., De la Hoz-Restrepo F. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine 2012, 30(11):1936-1943.
39. Strutton D.R., Farkouh R.A., Earnshaw S.R., Hwang S., Theidel U., Kontodimas S., et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect 2012, 64(1):54-67.
40. Rozenbaum M.H., Sanders E.A.M., van Hoek A.J., Jansen A.G.S.C., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340. PMID: 20519267.
41. Nakamura M.M., Tasslimi A., Lieu T.A., Levine O., Knoll M.D., Russell L.B., et al. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health 2011, 3(4):270-281.
42. Blank P.R., Szucs T.D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine 2012, 30(28):4267-4275.
43. Bin-Chia Wu D., Chang C.J., Huang Y.C., Wen Y.W., Wu C.L., Fann C.S.J. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health 2012, 15(1 Suppl.):S15-S19.
44. van Hoek A.J., Choi Y.H., Trotter C., Miller E., Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine 2012, 30(50):7205-7213.
45. Bakir M., Türel O., Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res 2012, 12(1).
46. Klok R.M., Lindkvist R.M., Ekelund M., Farkouh R.A., Strutton D.R. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther 2013, 35(2):119-134.
47. Hoshi S.l., Kondo M., Okubo I. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine 2013, 31:2762-2771.
48. Kulpeng W., Leelahavarong P., Rattanavipapong W., Sornsrivichai V., Baggett H.C., Meeyai A., et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?. Vaccine 2013, 31:2839-2847. PMID: 23588084.
49. Ayieko P., Griffiths U.K., Ndiritu M., Moisi J., Mugoya I.K., Kamau T., et al. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLOS ONE 2013, 8(6).
50. Gomez J.A., Tirado J.C., Navarro Rojas A.A., Castrejon Alba M.M., Topachevskyi O. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health 2013, 13(1).
51. Lee K.K.C., Chia Wu D.B., Topachevskyi O., Delgleize E., DeAntonio R. The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong. Value Health Reg Issues 2013, 2(1):64-74.
52. Petrova G. Study of the economic consequences of introduction of obligatory 10 valent conjugated pneumococcus vaccination in Bulgaria. Pediatriya 2009, 49(Suppl. 1):51-56.
53. Picazo J., Méndez C., Oyagüez I., Casado M.A., Guijarro P. Cost-utility analysis of the inclusion of new pneumococcal conjugate vaccines in the regional immunization program of the Autonomous Region of Madrid: impact on invasive pneumococcal disease. Vacunas 2010, 11(3).
54. Muciño-Ortega E., Mould-Quevedo J.F., Farkouh R., Strutton D. Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente. Value Health 2011, 14(5 Suppl.):S65-S70.
55. Morano R., Perez F., Brosa M., Perez Escolano I. Cost-effectiveness analysis of pneumococcal vaccination in Spain. Gac Sanit 2011, 25:267-273. PMID: 21640443.
56. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:494-501. PMID: 16732146.
57. Bergman A., Hjelmgren J., Ortqvist A., Wisloff T., Kristiansen I.S., Hogberg L.D., et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis 2008, 40(9):721-729.
58. Berto P., Gallio D., Principi N. Budgetary impact of pneumococcal conjugate vaccination of newborns. Ann Ig 2007, 19:281-291. PMID: 17658115.
59. Bjornsdottir M. Cost-effectiveness analysis of pneumococcal vaccination in Iceland. Laeknabladid 2010, 96:537-543. PMID: 20820070.
60. Bos J.M., Rumke H.C., Welte R., Spanjaard L., van Alphen L., Postma M.J. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Pharmacoeconomics 2006, 24:141-153. PMID: 16460135.
61. Claes C., Reinert R.R., von der Schulenburg J.-M.G. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 2009, 10:25-38. PMID: 18379830.
62. Constenla D.O. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publ 2008, 24(2):101-112.
63. Giglio N.D., Cane A.D., Micone P., Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine 2010, 28:2302-2310. PMID: 20064478.
64. Giorgi-Rossi P., Merito M., Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health Policy 2009, 89(2):225-238.
65. Gumán N.A., De La Hoz F. Cost effectiveness of heptavalent pneumococcal conjugate vaccine in populations of high risk in Colombia 2011.
66. Hubben G.A.A., Bos J.M., Glynn D.M., van der Ende A., van Alphen L., Postma M.J. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007, 25:3669-3678. PMID: 17360082.
67. Larraz C., Mourine O.H., Giglio N., Cane N., Garcia A.M. Cost-effectiveness of universal pneumococcal vaccination in Uruguay. Rev Panam Salud Publ 2010, 28(2):92-99.
68. Lee K.K.C., Rinaldi F., Chan M.K.U., Chan S.T.H., So T.M.T., Hon E.K.L., et al. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong. Value Health 2009, 12(Suppl. 3):42-48. PMID: 20586981.
69. Lloyd A., Patel N., Scott D.A., Runge C., Claes C., Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008, 9:7-15. PMID: 17333089.
70. Maria M., Uribe G.F.M. Estimated cost-effectiveness of heptavalent pneumococcal conjugated vaccine (PCV7) in Colombian Children Economics Studies Center, FEDESARROLLO, Colombia. Vaccine 2008.
71. Poirier B., De Wals P., Petit G., Erickson L.J., Pepin J. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2009, 27(50):7105-7109.
72. Postma M., Bos H.G., End Avd J., Alphen Lv. Cost-effectiveness of nationwide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Eur J Public Health 2006, 16:52-53.
73. Ray G.T., Pelton S.I., Klugman K.P., Strutton D.R., Moore M.R. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009, 27:6483-6494. PMID: 19720366.
74. Fregonese L., Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3:16.
75. Rubin J., McGarry L., Klugman K., Strutton D., Gilmore K., Hwang S., et al. TR4 public health and economic impact of 13-valent pneumococcal conjugate vaccine (PCV 13) in an influenza pandemic in Singapore and Hong Kong. Value Health 2010, 13(3):A9.
76. Silfverdal S.A., Berg S., Hemlin C., Jokinen I. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 2009, 27:1601-1608. PMID: 19146905.
77. Sinha A., Constenla D., Valencia J.E., O'Loughlin R., Gomez E., de la Hoz F., et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publ 2008, 24(5):304-313.
78. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-396. PMID: 17276779.
79. Sohn H.S., Suh D.-C., Jang E., Kwon J.-W. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea. J Manag Care Pharm 2010, 16:32-45. PMID: 20044845.
80. Tilson L., Usher C., Butler K., Fitzsimons J., O'Hare F., Cotter S., et al. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Value Health 2008, 11:898-903. PMID: 18489504.
81. Vespa G., Constenla D.O., Pepe C., Safadi M.A., Berezin E., de Moraes J.C., et al. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publ 2009, 26(6):518-528.
82. Wisloff T., Abrahamsen T.G., Bergsaker M.A.R., Lovoll O., Moller P., Pedersen M.K., et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006, 24:5690-5699. PMID: 16735083.
83. Aljunid S., Abuduxike G., Ahmed Z., Sulong S., Nur A.M., Goh A. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infect Dis 2011, 11.
84. Hoshi S.L., Kondo M., Okubo I. Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine 2012, 30(22):3320-3328.
85. Stoecker C., Hampton L.M., Moore M.R. 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2012, 30(44):6256-6262.
86. Wu D.B.C., Rinaldi F., Huang Y.C., Chang J.A., Chang C.J. Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis. J Formos Med Assoc 2013, 112(3):151-160.
87. Australian Government Department of Health National immunisation program schedule 2013, Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/nips-ctn [cited 08.12.14].
88. Ministry of Health (MOH), United Nations Children's Fund (UNICEF), World Health Organization (WHO) 2013 Botswana: post introduction evaluation of pneumococcal and rotarix vaccines in Botswana 2013.
89. Public Health Agency of Canada Canadian Immunization Guide - Pneumococcal Vaccine Ontario 2014, Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-pneu-eng.php [cited 08.10.14].
90. Lee L., Gu X.-X., Nahm M. Towards new broader spectrum pneumococcal vaccines: the future of pneumococcal disease prevention. Vaccines 2014, 2(1):112-128.
91. European Centre for Disease Prevention and Control (ECDC) Vaccine schedule 2014, ECDC, Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx [cited 08.12.14].
92. Hlatshwayo S. New pneumonia vaccine introduced in Swaziland. Times of Swaziland 2014.
93. Hortal M., Estevan M., Meny M., Iraola I., Laurani H. Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay. PLOS ONE 2014, 9(6):e98567.
94. Centers for Disease Control Prevention Recommended immunization schedule for persons aged 0 through 18 years - United States 2014, CDC, Atlanta, Available from: http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf [cited 08.12.14].
95. Berglund A., Ekelund M., Fletcher M.A., Nyman L. All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. PLOS ONE 2014, 9(11):e112211.
96. Centre for Health Protection Recommendations on the use of 13-valent pneumococcal conjugate vaccine in childhood immunisation programme 2011, CHP Scientific Committee Secretariat.
97. National Institute for Public Health and the Environment The National Immunisation Programme in the Netherlands: developments in 2013 2013, National Institute for Public Health and the Environment, Bilthoven.
98. Economic evaluation of 13 versus 10-valent pneumococcal conjugate vaccine in the Netherlands. 9th International Symposium on Pneumococci and Pneumococcal Diseases 2014, A.W.M. Suijkerbuijk, P. Vemer, M.J. Knol, A. Lugner, M. Al, A. Van der Ende (Eds.).
99. Marzouk M., Ferjani A., Bouafia N., Harb H., Ben Salem Y., Boukadida J. Serotype distribution and antimicrobial resistance of invasive and noninvasive pneumococcal isolates in Tunisia. Microb Drug Resist (Larchmont, NY) 2014, 21:85-89.
100. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502. PMID: 17071283.
101. Esposito S., Pugni L., Bosis S., Proto A., Cesati L., Bianchi C., et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005, 23:1703-1708. PMID: 15705475.
102. Kayhty H., Ahman H., Eriksson K., Sorberg M., Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005, 24:108-114. PMID: 15702037.
103. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001, 10(8):751-774.
104. Butler J.R., McIntyre P., MacIntyre C.R., Gilmour R., Howarth A.L., Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004, 22(9/10):1138-1149.
105. Baraff L.J., Lee S.I., Schriger D.L. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993, 12(5):389-394.
106. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect 2010, 61(2):114-124.
107. Edmond K., Clark A., Korczak V.S., Sanderson C., Griffiths U.K., Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(5):317-328.
108. Goetghebuer T., West T.E., Wermenbol V., Cadbury A.L., Milligan P., Lloyd-Evans N., et al. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 2000, 5(3):207-213.
109. Linstone H.A., Turoff M. The Delphi method: techniques and applications 2002, Addison-Wesley.
110. Morrow A., De Wals P., Petit G., Guay M., Erickson L.J. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007, 18(2):121-127.
111. McIntyre P.B., Berkey C.S., King S.M., Schaad U.B., Kilpi T., Kanra G.Y., et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997, 278(11):925-931.
112. Pomeroy S.L., Holmes S.J., Dodge P.R., Feigin R.D. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990, 323(24):1651-1657.
113. Design/setting of COMPAS: a Latin-American trial evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). 29th annual meeting of the European Society for Paediatric Infectious Disease (ESPID) 2011.
114. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-acquired pneumonia in Latin America. 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2011.
115. Palmu A.A., Jokinen J., Borys D., Nieminen H., Ruokokoski E., Siira L., et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381(9862):214-222.
116. Palmu A.A., Jokinen J., Nieminen H., Syrjanen R., Ruokokoski E., Puumalainen T., et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med 2014, 2(9):717-727.
117. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(3):187-195.
118. Black S., Shinefield H., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21:810-815. PMID: 12352800.
119. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006, 25:779-781. PMID: 16940833.
120. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
121. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Mak 2003, 23:76-82. PMID: 12583457.
122. De Wals P., Black S., Borrow R., Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin Ther 2009, 31(10):2152-2169.
123. Van Effelterre T., Moore M.R., Fierens F., Whitney C.G., White L., Pelton S.I., et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010, 28:3650-3660. PMID: 20359560.
124. Standaert B., Demarteau N., Talbird S., Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?. Vaccine 2010, 28(Suppl. 6):G30-G38.
125. Stancil J.M., Peters T.R., Givner L.B., Poehling K.A. Potential impact of accelerating the primary dose of pneumococcal conjugate vaccine in infants. Arch Pediatr Adolesc Med 2009, 163:422-425. PMID: 19414687.
126. Moulton L.H., O'Brien K.L., Reid R., Weatherholtz R., Santosham M., Siber G.R. Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study. J Biopharm Stat 2006, 16:453-462. PMID: 16892907.
127. Melegaro A., Choi Y.H., George R., Edmunds W.J., Miller E., Gay N.J. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010, 10:90.
128. Karlsson D., Jansson A., Normark B.H., Nilsson P. An individual-based network model to evaluate interventions for controlling pneumococcal transmission. BMC Infect Dis 2008, 8:83.
129. Hoti F., Erasto P., Leino T., Auranen K. Outbreaks of Streptococcus pneumoniae carriage in day care cohorts in Finland - implications for elimination of transmission. BMC Infect Dis 2009, 9:102.
130. Haber M., Barskey A., Baughman W., Barker L., Whitney C., Shaw K., et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007, 25:5390-5398. PMID: 17583392.
131. Barzilay E., O'Brien K., Kwok Y., Hoekstra R., Zell E., Reid R., et al. Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 2006, 24:904-913. PMID: 16203059.
132. Snedecor S.J., Strutton D.R., Ciuryla V., Schwartz E.J., Botteman M.F. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine 2009, 27:4694-4703. PMID: 19520197.
133. Nurhonen M., Cheng A.C., Auranen K. Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination. PLOS ONE 2013, 8(2).
134. Erasto P., Hoti F., Auranen K. Modeling transmission of multitype infectious agents: application to carriage of Streptococcus pneumoniae. Stat Med 2012, 31:1450-1463. PMID: 22354452.
135. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999, 5:336-345. PMID: 10341170.
136. Martcheva M., Thomasey D. Serotype replacement of vertically transmitted diseases through perfect vaccination. J Biol Syst 2008, 16(2):255-277.
137. Lipstich M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997, 94(12):6571-6576.
138. Auranen K., Eichner M., Leino T., Takala A.K., Makela P.H., Takala T. Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population. Epidemiol Infect. 2004, 132(15473159):947-957.
139. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004, 22(25/26):3312-3322.
140. Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008, 5(3):e74.
141. De Wals P., Lefebvre B., Markowski F., Deceuninck G., Defay F., Douville-Fradet M., et al. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014, 32(13):1501-1506.
142. Lim G.H., Wormsbecker A.E., McGeer A., Pillai D.R., Gubbay J.B., Rudnick W., et al. Have changing pneumococcal vaccination programmes impacted disease in Ontario?. Vaccine 2013, 31(24):2680-2685.
143. Pelton S.I., Weycker D., Klein J.O., Strutton D., Ciuryla V., Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010, 28(6):1575-1582.
144. Beutels P., Blommaert A., Hanquet G., Bilcke J., Thiry N., Sabbe M., et al. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood 2011, Belgian Health Care Knowledge Centre (KCE), Brussels.